Decrease in HbA1c with Bydureon is a key consideration for adults with type 2 diabetes when choosing an injectable therapy. Bydureon (exenatide prolonged-release) is a once-weekly GLP-1 receptor agonist licensed in the UK for use alongside diet and other antidiabetic agents. Clinical trials from the DURATION programme consistently demonstrate meaningful reductions in HbA1c, and NICE NG28 provides clear criteria for initiating and continuing treatment on the NHS. This article explains how Bydureon lowers blood sugar, what reductions to expect, and how monitoring and prescribing guidance applies in UK clinical practice.

How Bydureon Works to Lower Blood Sugar Levels

Bydureon mimics the GLP-1 incretin hormone, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying to reduce both fasting and post-prandial blood glucose levels.

Have any more questions about this? Message our pharmaceutical team to get more info →

Bydureon (exenatide prolonged-release) is a once-weekly injectable medication belonging to the glucagon-like peptide-1 (GLP-1) receptor agonist class. It is licensed for use in adults with type 2 diabetes mellitus — it is not indicated for type 1 diabetes or diabetic ketoacidosis — typically alongside dietary measures and other antidiabetic agents. Understanding how it works helps explain why it can produce a meaningful decrease in HbA1c over time.

Exenatide mimics the action of the naturally occurring incretin hormone GLP-1, which is released from the gut in response to food intake. By binding to GLP-1 receptors on pancreatic beta cells, Bydureon stimulates glucose-dependent insulin secretion — meaning it encourages insulin release only when blood glucose levels are elevated. This mechanism significantly reduces the risk of hypoglycaemia compared with some other antidiabetic agents such as sulfonylureas.

In addition to enhancing insulin secretion, Bydureon also:

• Suppresses glucagon release, reducing hepatic glucose output

• Slows gastric emptying, which blunts post-meal glucose spikes

• Reduces appetite, which can contribute to weight loss and indirectly improve glycaemic control

The prolonged-release formulation delivers a steady concentration of exenatide throughout the week, avoiding the peaks and troughs associated with twice-daily exenatide (Byetta). This consistent pharmacokinetic profile supports sustained reductions in both fasting and post-prandial blood glucose, ultimately contributing to a lower HbA1c over the course of treatment. The medication is administered as a subcutaneous injection once weekly.

Full prescribing information, including contraindications and special precautions, is available in the current Summary of Product Characteristics (SmPC) for Bydureon, accessible via the MHRA/EMC.

Clinical Evidence for HbA1c Reduction with Bydureon

The DURATION programme demonstrated mean HbA1c reductions of 1.3%–1.9% (14–21 mmol/mol) with Bydureon, with DURATION-1 showing superiority over twice-daily exenatide and DURATION-2 showing superiority over sitagliptin and pioglitazone.

The clinical evidence supporting a decrease in HbA1c with Bydureon is well established through a series of randomised controlled trials, most notably the DURATION (Diabetes Therapy Utilisation: Researching Changes in A1c, Weight and Other Factors Through Intervention with Exenatide Once Weekly) programme. These trials compared Bydureon against placebo, other GLP-1 receptor agonists, and alternative antidiabetic agents including insulin glargine and sitagliptin.

In the pivotal DURATION-1 trial (Drucker et al., Lancet, 2008), patients treated with Bydureon achieved a mean HbA1c reduction of approximately 1.9% (20.8 mmol/mol) from baseline over 30 weeks, compared with a reduction of 1.5% with twice-daily exenatide. The DURATION-2 trial (Bergenstal et al., Lancet, 2010) demonstrated that Bydureon produced superior HbA1c reductions compared with sitagliptin and pioglitazone. Across the DURATION programme, mean HbA1c reductions consistently ranged from approximately 1.3% to 1.9% (14–21 mmol/mol), depending on baseline HbA1c and background therapy.

The European Medicines Agency (EMA) reviewed the totality of this evidence as part of the authorisation process for Bydureon, as summarised in the published European Public Assessment Report (EPAR), confirming its efficacy in improving glycaemic control in adults with type 2 diabetes. UK real-world data, including the ABCD (Association of British Clinical Diabetologists) nationwide audit of once-weekly exenatide, have broadly corroborated these findings.

It is important to note that GLP-1 receptor agonists should not be used in combination with DPP-4 inhibitors (e.g., sitagliptin, alogliptin), as this combination is not recommended in UK clinical practice per NICE NG28. Clinical trial populations may also differ from everyday NHS patients in terms of comorbidities, adherence, and concomitant medications; nevertheless, the evidence base provides a reliable foundation for understanding the glycaemic benefits that can be expected with this treatment.

What HbA1c Decrease Can You Expect on Bydureon?

Most patients can expect an HbA1c reduction of 1.3%–1.9% (14–21 mmol/mol) within three to six months; higher baseline HbA1c is the strongest predictor of a larger absolute reduction.

For most people starting Bydureon, a clinically meaningful decrease in HbA1c can be expected within the first three to six months of treatment, provided the medication is used consistently and alongside appropriate lifestyle measures. Based on clinical trial data from the DURATION programme, the average reduction in HbA1c is in the region of 1.3% to 1.9% (approximately 14–21 mmol/mol), though individual responses vary considerably.

One of the most important predictors of the absolute HbA1c reduction is the baseline HbA1c level. Patients who begin treatment with a higher HbA1c — for example, above 9% (75 mmol/mol) — tend to experience larger absolute reductions than those who start with a value closer to target. This is a consistent finding across GLP-1 receptor agonist trials and reflects the glucose-dependent mechanism of action.

In addition to glycaemic improvements, many patients also experience:

• Weight loss of approximately 2–4 kg on average (as reported in the DURATION trials and the Bydureon SmPC), which can further support HbA1c reduction

• Modest reductions in systolic blood pressure, which have been observed in clinical trials; however, it is important to note that exenatide once-weekly did not demonstrate superiority for major adverse cardiovascular events (MACE) in the EXSCEL cardiovascular outcomes trial (Holman et al., NEJM, 2017), which showed non-inferiority compared with placebo

• Reduced post-prandial glucose excursions, contributing to overall glycaemic stability

It is important to have realistic expectations. Not all patients will achieve the same degree of HbA1c reduction, and some individuals may not respond adequately to GLP-1 receptor agonist therapy. In line with NICE NG28, treatment response should be reviewed at six months; if a clinically meaningful reduction in HbA1c of at least 11 mmol/mol (1%) has not been achieved, continuation of the medication should be reconsidered. Patients should discuss their individual targets and progress with their diabetes care team.

Factors That Influence Your HbA1c Response to Treatment

Baseline HbA1c, duration of diabetes, adherence to weekly injections, lifestyle factors, concomitant medications, and renal function all influence the degree of HbA1c reduction achieved with Bydureon.

The degree of HbA1c reduction achieved with Bydureon is not uniform across all patients, and several clinical and lifestyle factors can influence the magnitude of response. Understanding these variables can help patients and clinicians set appropriate expectations and optimise treatment outcomes.

Baseline HbA1c is the single strongest predictor of absolute HbA1c reduction, as discussed above. Beyond this, the duration of type 2 diabetes plays a role — patients with longer-standing disease may have greater beta-cell dysfunction, which can limit the insulin-stimulating effects of GLP-1 receptor agonists. Residual beta-cell function is therefore an important determinant of response.

Other factors that may influence HbA1c outcomes include:

• Adherence to weekly injections — missed doses reduce the consistency of drug exposure

• Dietary habits and physical activity — lifestyle modifications remain a cornerstone of diabetes management and amplify pharmacological effects

• Concomitant medications — the addition of Bydureon to metformin or SGLT-2 inhibitors may produce additive glycaemic benefits; however, combination with a DPP-4 inhibitor is not recommended per NICE NG28

• Body weight — patients who achieve greater weight loss on Bydureon may also see more pronounced HbA1c improvements

• Injection technique and site rotation — incorrect subcutaneous injection technique can affect drug absorption; injection-site nodules are a commonly reported reaction with exenatide prolonged-release and are typically self-limiting, but persistent or troublesome nodules should be discussed with a healthcare professional

Renal impairment: According to the Bydureon SmPC, exenatide prolonged-release is not recommended in patients with severe renal impairment (eGFR below 30 mL/min/1.73 m²). Caution is also advised in moderate renal impairment. There is no dose-adjustment strategy; prescribers should refer to the current SmPC and NICE NG28 for guidance on suitable alternatives.

Hypoglycaemia risk: When Bydureon is used alongside a sulfonylurea or insulin, the risk of hypoglycaemia is increased. Clinicians may need to consider reducing the dose of the sulfonylurea or insulin when initiating Bydureon, in line with SmPC and NICE NG28 recommendations.

Patients experiencing persistent nausea or gastrointestinal side effects — which are common in the early weeks of treatment — should speak to their GP or diabetes nurse, as these symptoms can affect dietary intake and adherence, indirectly influencing HbA1c outcomes.

NICE Guidance and Prescribing Bydureon on the NHS

NICE NG28 permits Bydureon as part of triple therapy or as an alternative to insulin, with continuation conditional on achieving at least 11 mmol/mol (1%) HbA1c reduction and 3% weight loss within six months.

In the United Kingdom, the prescribing of Bydureon on the NHS is guided primarily by NICE NG28: Type 2 diabetes in adults — management, which sets out when GLP-1 receptor agonists, including exenatide prolonged-release, should be considered as part of an individualised treatment pathway.

According to NICE NG28, a GLP-1 receptor agonist such as Bydureon may be considered:

• As part of triple therapy when dual therapy with oral antidiabetic agents has not achieved adequate glycaemic control, or

• When insulin therapy would otherwise be the next treatment step but is considered unsuitable — for example, due to significant obesity or concerns about hypoglycaemia

• Particularly in patients with a BMI of 35 kg/m² or above (with appropriate adjustment for ethnicity and individual clinical factors) where obesity-related comorbidities are present, or in patients with a BMI below 35 kg/m² where insulin would have significant occupational implications or where weight loss would benefit other significant obesity-related comorbidities

NICE NG28 specifies that treatment should only be continued if the patient achieves a reduction in HbA1c of at least 11 mmol/mol (1%) and a weight loss of at least 3% of initial body weight within six months. If these thresholds are not met, the medication should be discontinued.

It is important to note that GLP-1 receptor agonists should not be prescribed in combination with DPP-4 inhibitors in UK clinical practice, as this combination is not recommended by NICE NG28.

Prescribers should also consult the MHRA and the current SmPC for up-to-date safety information, including guidance on pancreatitis risk and renal impairment. NHS Scotland follows Scottish Medicines Consortium (SMC) guidance, which may differ; clinicians in Scotland should refer to the relevant SMC advice. Patients should always discuss their eligibility and treatment options with their GP or specialist diabetes team.

Monitoring HbA1c and Reviewing Your Diabetes Management

NICE NG28 recommends HbA1c measurement every three to six months during treatment initiation and a formal six-month review to assess glycaemic response, weight change, and tolerability before continuing Bydureon.

Regular monitoring of HbA1c is essential for assessing the effectiveness of Bydureon and guiding ongoing diabetes management decisions. In line with NICE NG28, HbA1c should typically be measured every three to six months when treatment is being initiated or adjusted, and at least annually once stable glycaemic control has been achieved.

For patients starting Bydureon, a formal review at six months is recommended to assess both glycaemic response and weight change, in accordance with the NICE NG28 continuation criteria outlined above. At this review, the diabetes care team will consider:

• Whether the target HbA1c reduction of at least 11 mmol/mol (1%) has been achieved

• Whether the patient has lost at least 3% of their initial body weight

• The tolerability of the medication, including any gastrointestinal side effects

• Whether any changes to concomitant therapy are required

Patients should be aware of the following reasons to contact their GP or diabetes nurse promptly:

• Persistent or severe nausea, vomiting, or abdominal pain — particularly pain that is severe, persistent, or radiates to the back, which may rarely indicate pancreatitis; further doses should be withheld and urgent medical review sought

• Signs of hypoglycaemia, particularly if also taking a sulfonylurea or insulin

• Injection-site nodules that are persistent, painful, or do not resolve over time (mild, self-limiting nodules are common with exenatide prolonged-release)

• Any unexplained deterioration in kidney function

Beyond HbA1c, a comprehensive diabetes review should also include assessment of blood pressure, lipid profile, renal function, and screening for diabetes-related complications. Achieving a meaningful decrease in HbA1c with Bydureon is an important goal, but it forms part of a broader, holistic approach to reducing the long-term risks of cardiovascular disease, nephropathy, retinopathy, and neuropathy.

If you experience a suspected side effect from Bydureon, you can report it directly to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. Open communication with your healthcare team remains the most effective way to optimise your diabetes management.

Frequently Asked Questions